Zhi Tong Cai Jing·2026-02-02 07:03Core Viewpoint - Rongchang Biopharma (09995) has announced a significant increase in expected revenue and profit for the fiscal year 2025, leading to a nearly 4% rise in stock price following the earnings forecast [1] Financial Performance - The company anticipates a revenue of approximately RMB 3.25 billion for 2025, representing an increase of about RMB 1.533 billion, or 89% year-on-year [1] - Expected net profit attributable to the parent company is projected to be around RMB 716 million, marking a turnaround from losses in the previous year [1] - The net profit after excluding non-recurring items is estimated at RMB 78.5 million, also indicating a return to profitability compared to the previous year [1] Product and Market Development - Core products, Taitasip and Vidisitimab, are expected to see rapid growth in domestic sales, serving as the main drivers of revenue growth [1] - The company has secured a significant partnership with Vor Biopharma Inc., granting exclusive global development and commercialization rights for Taitasip outside Greater China, which will substantially increase technology licensing revenue [1] Cost Management and Efficiency - The company has implemented measures to optimize management and iterate production processes, resulting in reduced unit production costs and improved gross margins [1] - A notable decrease in sales expense ratio has also contributed to the overall improvement in profitability efficiency [1]